



BEAUTOX BAR

Beautox Bar LLC • 7372 Kirkwood Court N, Maple Grove, MN 55369
Beautox Bar WBL LLC • 4503 Allendale Drive, White Bear Lake, MN 55127
Phone: 763-205-6952 • Website: www.beautoxbar.com

PEPTIDE THERAPY INFORMED CONSENT AND ARBITRATION AGREEMENT

Injectable Self-Administration • Sublingual / Oral Dissolvable Strips • Class-Wide Peptide Therapies

Effective Date: September 26, 2026 (or date of signature below)

Client Name (print): _____

Date of Birth (optional): _____ **Date:** _____

1. Purpose and Background

Please read this entire form carefully. It explains the nature, purpose, benefits, risks, alternatives, limitations, and regulatory status of peptide therapy that may be prescribed or dispensed for you at Beautox Bar, including injectable peptides for self-administration after training and sublingual / orally dissolving thin-film or strip peptides for at-home self-administration after instruction. Ask questions before you sign. Signing means you understand the information, have had your questions answered, and voluntarily consent to treatment as described. You may refuse or stop treatment at any time. This is one consolidated consent covering both routes of administration for peptide therapies as a class; it is not a separate signature packet for each product or route.

2. Clinic Entities Providing Care

I consent to evaluation and treatment by Beautox Bar LLC (Maple Grove, MN) and/or Beautox Bar WBL LLC (White Bear Lake, MN) (together, "Beautox Bar," the "Clinic," or "we/us"), including their medical director(s), licensed medical providers, and authorized clinic team members. Care may be provided at either location. This consent and the Arbitration Agreement below apply to services and related products provided by both entities.

3. Medications / Products Covered (Class-Wide Peptide Therapy)

This consent covers peptide therapy as a class that your licensed provider may prescribe or dispense for you when clinically appropriate and lawfully available, including (non-exhaustive examples — not a menu promising any particular product):

- Injectable peptides for clinic and/or at-home self-administration after training (for example, wellness, regenerative, aesthetic, metabolic, recovery, or related uses).
- Sublingual / orally dissolving thin-film or strip peptides for at-home self-administration after instruction.
- Wellness, regenerative, aesthetic, metabolic, recovery, and related peptide uses as clinically appropriate under applicable law.
- Named investigational example — Ultratrutide (SP-GHR-001a): investigational / NOT FDA-approved as a finished drug product for human use. It has been marketed in some channels as a research peptide. Human



safety and effectiveness have not been established. If ever considered for you, it will be only if lawfully available through licensed channels, with additional counseling; marketing claims are not proven clinical benefits.

- Other peptide products your provider may prescribe if and only if they are lawfully available under applicable federal and Minnesota law.

This list is illustrative. Listing a peptide as an example does not mean Beautox Bar currently offers it, that it is FDA-approved, that it may lawfully be compounded, or that it is appropriate for you. Your specific product(s), dose, route, and schedule will be documented in your chart and discussed with you.

4. Regulatory Status (FDA / Compounding / Investigational / Off-Label)

I understand the following important distinctions about peptide products that may be discussed or prescribed:

- Most wellness, regenerative, and aesthetic peptides used in clinics are NOT FDA-approved finished drug products for those indications. FDA approval of a finished drug means FDA has reviewed safety, effectiveness, and manufacturing quality for labeled uses; absence of that approval means those assurances do not apply in the same way.
- Compounded drugs are NOT FDA-approved. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act) compounding framework (sections 503A for traditional pharmacy compounding and 503B for outsourcing facilities), FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Compounded products may differ from brand products in purity, strength, quality, labeling, and safety profile.
- Bulk compounding of many popular peptides is restricted. Under section 503A, bulk substances generally must comply with an applicable USP/NF monograph, be components of FDA-approved drugs, or appear on FDA's 503A Bulks List. Pharmacy Compounding Advisory Committee (PCAC) advisory votes (for example, July 2026 recommendations regarding certain peptides such as BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon) are NONBINDING and do NOT by themselves authorize compounding until FDA completes notice-and-comment rulemaking and places a substance on the applicable list (or other lawful pathway applies).
- Products labeled "for research use only" (RUO) or "not for human consumption" are NOT approved medications for patient treatment. FDA has warned against selling or using unapproved peptides (including some GLP-1-related and other metabolic peptides) falsely labeled for research while directed at consumers. Beautox Bar will NOT knowingly dispense illegal research chemicals labeled not-for-human-use as patient medications.
- Beautox Bar only provides peptide products that are lawfully available through licensed providers, pharmacies, and/or outsourcing facilities under applicable federal and Minnesota law.
- Off-label use: When a peptide drug IS FDA-approved for one indication, a licensed provider may prescribe it for another use based on clinical judgment (off-label use). Off-label prescribing of an FDA-approved drug is different from using an unapproved, compounded, investigational, or research-only product. Your provider will explain which category applies to any product prescribed for you.



- Investigational products (including Ultratride / SP-GHR-001a if ever considered): human safety and effectiveness are not established; additional counseling is required; no marketing claims are treated as proven benefits.

5. Minnesota Pharmacy and Practice Standards

In plain language, Minnesota regulates compounding and clinical practice as follows (this summary is for patient information and is not a complete statement of the law):

- Compounding is governed by Minn. Stat. § 151.253 and Minnesota Board of Pharmacy rules. Sterile compounding follows USP <797>; nonsterile compounding follows USP <795> (see also Minn. R. 6800.3300).
- Patient-specific prescriptions are generally required for traditional (503A) compounding. Vague “office use” human compounding that amounts to manufacturing without meeting applicable federal requirements is not permitted.
- Clinical care is provided under applicable Minnesota Board of Medical Practice and/or Board of Nursing standards (including Minn. Stat. ch. 147 and nursing practice acts as appropriate for the licensed clinician involved).
- Informed consent and patient rights are addressed under Minn. Stat. § 144.651 (see Minnesota Informed Consent Notice below).

6. Potential Benefits

Depending on the specific peptide, route, and your clinical situation, possible goals of therapy may include support for wellness, recovery, regenerative or aesthetic aims, metabolic support, or other clinician-directed objectives. For many clinic peptides, clinical evidence in humans is limited, preliminary, or extrapolated from research settings. Benefits are not guaranteed. Individual response varies widely. No particular cosmetic, metabolic, recovery, or wellness outcome is promised.

7. Alternatives

Alternatives include declining peptide therapy entirely; lifestyle measures (nutrition, exercise, sleep, stress management); FDA-approved therapies for any diagnosed condition (when available); other prescription or over-the-counter treatments recommended by your primary care provider or specialists; and watchful waiting. I have had the opportunity to ask about alternatives, including declining treatment.

8. Risks and Possible Side Effects

All medications and compounded products involve risk. Possible side effects and risks of peptide therapy (injectable and/or sublingual) include, but are not limited to:

- Injection-site reactions (if injectable): redness, itching, swelling, bruising, discomfort, nodule formation, or infection at the injection site
- Oral / mucosal irritation (if sublingual / dissolvable strips): mouth, tongue, or throat irritation, altered taste, numbness, or local allergic reaction



- Systemic effects: fatigue, headache, nausea, dizziness, flushing, changes in appetite, or general flu-like feelings
- Allergic or hypersensitivity reactions (rash, itching, swelling; rarely severe / anaphylaxis — seek emergency care for trouble breathing or facial/throat swelling)
- Blood sugar changes (especially with peptides that may affect metabolism or if I also use diabetes medicines) — hypoglycemia or hyperglycemia may occur
- Dehydration, especially with nausea, vomiting, or reduced oral intake
- Unknown or incompletely characterized long-term risks for many peptides that lack robust, long-duration human clinical trial data for the intended use
- Product variability risk for compounded formulations (purity, potency, sterility, beyond-use dating) compared with FDA-approved finished drugs
- Unsatisfactory result, no benefit, or need to discontinue therapy
- Drug, supplement, and peptide-peptide interactions (see below)

This list is not exhaustive. Product-specific counseling, pharmacy labels, and any Medication Guide (when available) also apply. I agree to promptly report concerning symptoms to Beautox Bar and to seek emergency care when indicated.

9. Contraindications, Use Caution, and Drug / Supplement Interactions

I understand peptide therapy may be inappropriate or require special caution if I have certain conditions. Eligibility is determined by my provider after history, examination, and indicated testing. I agree to disclose, before and during treatment:

- Allergies to any peptide, preservative, or compounding additive
- History of cancer, active malignancy, or unexplained growths (when relevant to the peptide class under consideration)
- Autoimmune, endocrine, kidney, liver, heart, or bleeding disorders
- Diabetes, blood sugar dysregulation, or use of insulin / other glucose-lowering medicines
- History of severe allergic reactions or anaphylaxis
- Pregnancy, possible pregnancy, plans to become pregnant, or breastfeeding / lactation
- All prescription drugs, over-the-counter medicines, supplements, herbs, other peptides, and weight-loss products I take or have recently taken
- Any prior adverse reaction to peptide therapy or related injections / oral films

I will not start, stop, or change other prescribed medicines without guidance from the prescribing clinician. Combining multiple peptides, supplements, or weight-loss agents without provider knowledge increases risk.

10. Pregnancy and Nursing Attestation

I will inform my Beautox Bar provider if I am pregnant, think I may be pregnant, plan to become pregnant, or am breastfeeding / nursing. I understand I may be advised to avoid peptide therapy in these circumstances because safety data are often limited or absent. I agree to notify the Clinic immediately if my pregnancy or nursing status changes while under this consent.



11. PART A — Injectable Self-Administration

If injectable peptide therapy is prescribed for me (clinic administration and/or at-home self-injection), I acknowledge that I have received or will receive education covering:

- Prescribed dose, titration (if any), timing, and what to do for a missed dose
- Sterile technique, hand hygiene, vial/syringe/pen handling, and aseptic preparation
- Recommended injection sites (commonly abdomen, thigh, or upper arm as taught), site rotation, and avoiding muscle or vein injection unless specifically directed
- Safe sharps disposal in an FDA-cleared sharps container (or heavy-duty plastic household container with a tight lid if permitted locally); no loose needles in household trash or recycling
- Storage and temperature requirements (refrigeration or room-temperature limits, light protection, beyond-use / expiration dating) exactly as stated on the pharmacy or product label

I agree never to share medications, pens, vials, syringes, or needles with another person; to use a new sterile needle for each injection; and to follow only the dose prescribed for me. I will not increase, decrease, or combine doses on my own.

12. PART B — Sublingual / Dissolvable Self-Administration

If sublingual or orally dissolving thin-film / strip peptide therapy is prescribed for me, I acknowledge that I have received or will receive instruction covering:

- Placement under the tongue (or as otherwise directed) and allowing the strip / film to dissolve fully without chewing or swallowing prematurely unless instructed otherwise
- Prescribed dose, frequency, timing relative to food or drink, and storage
- Missed-dose instructions as provided by my provider or pharmacy label
- Stopping the product and contacting the Clinic promptly if I experience mouth/throat swelling, severe irritation, rash, trouble breathing, dizziness, or other concerning reactions

Ultratrutide (SP-GHR-001a) — Investigational Disclosure (If Applicable)

If Ultratrutide (SP-GHR-001a) is among the products dispensed or prescribed for me (including any sublingual / dissolvable presentation), I specifically acknowledge: it is investigational and NOT FDA-approved; human safety and effectiveness have not been established; some channels market related materials as research peptides not for human consumption; Beautox Bar will only consider it if lawfully available through licensed providers / pharmacies / outsourcing facilities; marketing claims are not proven benefits; and I have received (or will receive) additional counseling before use. This class consent still applies; product-specific chart notes and counseling supplement it.

13. What to Expect, Follow-Up, and When to Call

A typical care pathway may include consultation and history; indicated labs; product selection and dosing plan; training for self-administration; follow-up visits; and adjustments based on response and tolerability. Timelines and visit frequency vary.



Contact Beautox Bar (763-205-6952) promptly for:

- Persistent or worsening side effects (nausea, dizziness, fatigue, local irritation)
- Injection-site problems that worsen or look infected
- Questions about dosing, missed doses, storage, or technique
- New medications, supplements, or health conditions after starting therapy

Call 911 or go to the nearest emergency room for:

- Signs of severe allergic reaction (trouble breathing, swelling of face/lips/tongue, widespread hives)
- Chest pain, fainting, severe dizziness, seizure, or other emergency symptoms
- Severe hypoglycemia that does not respond to usual treatment (if applicable)
- Thoughts of harming myself — also contact local crisis resources / 988 as appropriate

Beautox Bar does not provide 24-hour emergency services. For medical emergencies, call 911.

14. No Guarantee of Results

I understand that results from peptide therapy are not guaranteed. Individual response varies. Limited or preliminary evidence for many peptides means expected benefits may not occur. No particular aesthetic, regenerative, metabolic, recovery, or wellness outcome is promised.

15. Financial Responsibility

I understand that peptide therapy is often elective and frequently not covered by health insurance. I am responsible for payment of fees for consultations, medications / compounded products, supplies, labs, and related services according to Beautox Bar policies explained to me. If I choose to seek insurance reimbursement, that is my responsibility. Fees are generally non-refundable once services or medication have been provided, and dissatisfaction with results alone does not create a right to a refund. If my account becomes unpaid or a payment is reversed (including chargebacks without a good-faith basis), I may be responsible for reasonable collection costs permitted by Minnesota law, in addition to amounts owed.

16. Assumption of Risk and Softened Release

I voluntarily assume the risks of peptide therapy that have been explained to me, including known side effects and the possibility of unknown or incompletely characterized risks for certain peptides. To the fullest extent permitted under Minnesota law, I release Beautox Bar LLC, Beautox Bar WBL LLC, their medical director(s), licensed medical providers, employees, contractors, and agents from claims arising from known risks and expected side effects of properly performed peptide therapy as described in this consent—EXCEPT that this release does not apply to claims based on gross negligence, willful or wanton misconduct, or intentional misconduct, or to claims that cannot be waived under Minnesota law (including Minn. Stat. § 604.055 regarding greater-than-ordinary negligence). This is not an absolute waiver, hold-harmless, defend, or indemnify obligation for ordinary negligence, and it does not require me to defend or indemnify the Clinic against third-party claims beyond what Minnesota law permits.



17. Clinical Photography

I understand that clinical photographs and/or videos may be taken for my medical record to document treatment areas and monitor progress. These records are part of my confidential medical file and will not be released without my express written consent, except as required by law.

I further understand that Beautox Bar may request permission to use photographs and/or videos (which will not identify me by name) for educational, marketing, and promotional purposes, including but not limited to the clinic's website, social media, and printed materials. I will not receive compensation for the use of these images.

18. Arbitration Agreement

Please read this Arbitration Agreement carefully. By signing this document, you knowingly and voluntarily agree to resolve covered disputes through binding arbitration rather than through a court or jury trial, as described below. This Agreement is governed by the Minnesota Uniform Arbitration Act, Minn. Stat. ch. 572B, and, where applicable, the Federal Arbitration Act, 9 U.S.C. §§ 1 et seq.

Article 1 — Agreement to Arbitrate; Jury / Court Trial Waiver

Any dispute arising out of or relating to peptide therapy or related services or products provided by Beautox Bar LLC and/or Beautox Bar WBL LLC under this consent—including claims for medical malpractice or professional negligence (that is, whether any medical services were unnecessary or unauthorized or were improperly, negligently, or incompetently rendered), and related non-malpractice disputes arising out of or relating to the professional relationship, services, or products—will be determined by submission to binding arbitration as provided by Minnesota law, and not by a lawsuit or resort to court process, except as Minnesota law provides for judicial review of arbitration proceedings. By signing this Agreement, Client (also referred to as “you”) and Beautox Bar LLC and/or Beautox Bar WBL LLC (together with their providers, employees, agents, and associates, “Beautox Bar”) are each giving up their constitutional right to have any such dispute decided in a court of law before a jury, and instead are accepting the use of binding arbitration. This waiver is knowing and voluntary.

Article 2 — Scope; Arbitrability; Reserved Rights

This Agreement applies to claims asserted by Client, Client's heirs, spouse (including claims for loss of consortium), children (born or unborn), guardians, or other persons claiming through Client, relating to peptide therapy and related Clinic services or products. This Agreement applies to claims that exceed the jurisdictional limit of Minnesota small-claims (conciliation) court.

Gateway issues of whether an agreement to arbitrate exists, or whether a controversy is subject to arbitration, are decided by a court as provided by Minnesota law (see Minn. Stat. § 572B.06(b)). Nothing in this Agreement is intended to conflict with that statute.

Nothing in this Agreement limits Client's right to report concerns to licensing boards, the FDA, the U.S. Department of Health and Human Services Office for Civil Rights (OCR), or other government agencies, or to seek



emergent medical care. Nothing in this Agreement waives nonwaivable rights under Minn. Stat. § 572B.04, including the right to be represented by a lawyer.

Article 3 — Procedures, Seat, Fees, Confidentiality, and Award

A demand for arbitration must be made in writing and delivered to the other party. Arbitration shall be conducted before one (1) neutral arbitrator mutually selected by the parties. If the parties cannot agree on a neutral arbitrator within a reasonable time, the American Arbitration Association (AAA) or a Minnesota court of competent jurisdiction may appoint one as provided by law. Arbitration shall be conducted under the AAA Commercial Arbitration Rules (or any successor rules), to the extent consistent with this Agreement and Minnesota law, unless the parties agree otherwise in writing.

The seat and venue of arbitration shall be in Minnesota, in Hennepin County or Ramsey County (including the county of the Clinic's applicable principal office for the location where care was primarily provided, when consistent with this seat language). Proceedings shall be confidential, except as needed to enforce this Agreement or an award, or as required by law. Each party shall bear its own attorneys' fees and costs, and the fees and expenses of the neutral arbitrator shall be shared equally, unless applicable law or the arbitrator's award provides otherwise. Minnesota substantive law (including any applicable damages limitations) shall apply to the merits of the dispute.

The arbitrator's award shall be final and binding. Either party may seek confirmation of the award as a judgment in a Minnesota court of competent jurisdiction as provided by Minn. Stat. ch. 572B and applicable law.

Article 4 — General Provisions

All claims arising out of the same incident or course of treatment shall be resolved in one arbitration proceeding where practicable. Filing a demand for arbitration within the applicable statute of limitations preserves the claim for arbitration purposes to the same extent as filing a civil action would. Failure to pursue a claim with reasonable diligence, or to demand arbitration within the time allowed by Minnesota law, may result in waiver or bar of the claim as provided by applicable law.

Article 5 — Revocation (30 Days)

Client may revoke this Arbitration Agreement by giving written notice to the Clinic within thirty (30) days after the date Client signs this document. Written notice of revocation must be delivered to Beautox Bar LLC at 7372 Kirkwood Court N, Maple Grove, MN 55369, or Beautox Bar WBL LLC at 4503 Allendale Drive, White Bear Lake, MN 55127 (or such other address as the Clinic may designate). If this Agreement is not revoked within that thirty-day period, it governs professional services thereafter and disputes within its scope. Revocation of the Arbitration Agreement does not by itself revoke informed consent for treatment; treatment consent may be revoked separately in writing as stated below.

Article 6 — Retroactive Effect



By signing this Agreement, Client intends that it cover professional services and related peptide products rendered before the signature date (including any earlier visits related to peptide therapy) as well as services on and after the signature date, and that it be effective as of the date of Client's first professional peptide-therapy services with Beutox Bar LLC and/or Beutox Bar WBL LLC. No separate initials are required for this Article.

19. Minnesota Informed Consent Notice

Under Minnesota law, patients are entitled to complete and current information about their diagnosis, proposed treatment, alternatives, risks, and prognosis in language they can reasonably understand, and have the right to refuse treatment after receiving that information. See Minn. Stat. § 144.651, subd. 9 (information about treatment) and subd. 12 (right to refuse care). Obtaining informed consent for tests, procedures, and treatments is also a recognized professional obligation for physicians licensed in Minnesota (see Minn. Stat. ch. 147) and for nurses under applicable nursing practice acts and Board of Nursing standards as appropriate for the licensed clinician involved. By signing this form, I confirm that I have received understandable information about peptide therapy (injectable and/or sublingual as applicable), alternatives, risks, regulatory status, and contraindications, have had a chance to ask questions, and am consenting voluntarily.

20. Client Acknowledgements

By signing this consent, I state and confirm that:

- (1) I have disclosed my relevant medical history, medications, allergies, supplements, other peptides, weight-loss products, and conditions (including pregnancy / nursing status as applicable).
- (2) I have read and understand this consolidated consent form covering injectable and sublingual / dissolvable peptide therapy as a class (or had it read to me).
- (3) I understand the FDA / compounding / RUO / investigational / off-label distinctions described above, including that compounded drugs are not FDA-approved and that PCAC advisory votes do not by themselves authorize compounding.
- (4) I understand Beutox Bar only provides peptide products that are lawfully available through licensed providers / pharmacies / outsourcing facilities and will not knowingly dispense illegal research chemicals labeled not-for-human-use as patient medications.
- (5) I agree to follow aftercare, self-administration, storage, missed-dose, sharps (if applicable), and follow-up instructions for the route(s) prescribed.
- (6) I understand that results are not guaranteed and that evidence for many peptides is limited.
- (7) I have received the Minnesota informed consent information above; my questions have been answered to my satisfaction.
- (8) I knowingly and voluntarily agree to the Arbitration Agreement in Section 18, including the jury / court trial waiver, subject to my 30-day written revocation right for arbitration.
- (9) I consent voluntarily to peptide therapy as described and to subsequent related treatments under this consent for three hundred sixty-five (365) days from the date of my signature, unless I revoke consent sooner in writing. I may stop treatment at any time.



21. Acknowledgment and Consent

I consent to peptide therapy (injectable self-administration and/or sublingual / dissolvable administration, as indicated above and as prescribed for me) by Beautox Bar LLC and/or Beautox Bar WBL LLC and authorized providers. I have read the information above (or had it read to me), including the Arbitration Agreement, and am satisfied with the informed consent process. I hereby give consent to perform this and subsequent related treatments under this consent for 365 days from the date below, unless I revoke it sooner in writing delivered to the Clinic. I understand I may ask questions at any time and may withdraw consent for future treatments. A single signature below covers both treatment consent and the Arbitration Agreement; there are no separate "OR" acknowledgment blocks and no patient-initials lines on this form.

Client Name (print): _____

Client Signature: _____

Date: _____

Clinic Team Member Name (print): _____

Clinic Team Member Signature: _____

Date: _____

This consent applies to services provided by Beautox Bar LLC — 7372 Kirkwood Court N, Maple Grove, MN 55369 and Beautox Bar WBL LLC — 4503 Allendale Drive, White Bear Lake, MN 55127. Phone: 763-205-6952 • www.beautoxbar.com

Form date context: September 26, 2026 (client date fields left blank for completion at signing). Referenced for patient information include FD&C Act §§ 503A/503B; Minn. Stat. §§ 144.651, 151.253, 604.055; Minn. Stat. ch. 147 & 572B; Minn. R. 6800.3300; USP <795>/<797>.